Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

MXCT MaxCyte Inc

3,88

0,18 (4,86%)

Après les heures de négociation

Dernière mise à jour : 00:56:39

Retardé de 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/03/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/12/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Dominick Iadicicco, as a duly authorized representative of STIFEL, as attorney-in-fact for Stanley C Erck

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

MaxCyte (NASDAQ:MXCT)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024

Plus de graphiques de la Bourse MaxCyte

MaxCyte (NASDAQ:MXCT)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024

Plus de graphiques de la Bourse MaxCyte

Actualités MaxCyte Inc

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
Vendredi 11 Octobre 2024 ( il y a 12 heures) • GlobeNewswire Inc.

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
Jeudi 10 Octobre 2024 ( il y a 2 jours) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 2 Octobre 2024 ( il y a 1 semaine) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lundi 30 Septembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Jeudi 26 Septembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 18 Septembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Mercredi 18 Septembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
Lundi 16 Septembre 2024 ( il y a 4 semaines) • GlobeNewswire Inc.

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
Jeudi 5 Septembre 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Mardi 3 Septembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 28 Août 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mardi 6 Août 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Plus d'articles sur MaxCyte Inc

JP Morgan Chase

Cie de SaintGobain

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales